Asset profile
Traneurocin
Small molecule
Evidence outlook · lead readout
NCT03538522 · Mild Cognitive Impairment, Alzheimer Disease, Alzheimer Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Cognitive Impairment, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Cognitive Disorder
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT03538522: The study randomized 126 participants to three traneurocin doses or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary clinical endpoint was change in the Clinical Dementia Rating Scale–Sum of Boxes at Week 24, but the registry does not report whether this endpoint was met.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.